A Phase 3 interventional study of ruxolitinib tablets and Best Available Therapy (BAT) in Polycythemia Vera, sponsored by Incyte Corporation. Completed at 102 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-06.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing ruxolitinib in Polycythemia Vera — 5 open to participants now, 8 under way, 1 of them phase 3. ruxolitinib · Polycythemia Vera.
Among the 17 studies testing ruxolitinib in Polycythemia Vera, this one is the 3rd largest by enrollment, is one of 2 that started in 2010, is one of 5 in phase 3, and was the 3rd registered.
279 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.
Browse Polycythemia Vera studies →5 of the 17 studies testing ruxolitinib in Polycythemia Vera are open now, in 3 countries. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
University of Birmingham · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 5 · Phase 4 1
First in 2007; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 222 is above the median of 52 across 205 interventional studies indexed under Polycythemia Vera.
Median enrollment 110 across the 17 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 17 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Incyte Corporation has 6 studies filed under Polycythemia Vera — fewer than ten, so there is no comparison to draw.
4 of the studies testing ruxolitinib in Polycythemia Vera that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT04644211Massachusetts General HospitalRuxolitinib in Thrombocythemia and Polycythemia Vera | 2027-07 |
| NCT04282187University of WashingtonDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | 2027-11-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies testing ruxolitinib in Polycythemia Vera, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of ruxolitinib (INC424) to Best Available Therapy (BAT) in participants with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg once a day (QD) to 25 mg BID based on safety and efficacy
Drug: ruxolitinib tablets
Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
Other: Best Available Therapy (BAT)
Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
Also known as: BAT could include:, Hydroxyurea, IFN/PEG-IFN, Pipobroman, Anagrelide, Lenalidomide, Pomalidomide, Observation only
The Percentage of Participants Achieving a Primary Response at Week 32
Primary response was defined as having achieved hematocrit control (the absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32) and Spleen Volume Reduction (a greater than or equal to 35% reduction from baseline in spleen volume at Week 32).
Time frame: 32 Weeks
The Percentage of Participants Achieving a Durable Primary Response at Week 48
Durable Primary Response was defined as any participant who achieved the primary outcome measure and who maintained their response up to 48 weeks after randomization.
Time frame: 48 Weeks
The Percentage of Participants Achieving Complete Hematological Remission at Week 32
Complete Hematological Remission at Week 32 was defined as any participant who achieved hematocrit control with a platelet count less than or equal to 400 X 10\^9/L and a white blood cell count less than or equal to 10 X 10\^9/L.
Time frame: 32 Weeks
The Percentage of Participants Who Achieved a Durable Complete Hematological Remission at Week 48
Durable Complete Hematological Remission was defined as any participant who achieved Complete Hematological Remission at Week 32 and maintained their response up to 48 weeks after randomization.
Time frame: 48 Weeks
The Percentage of Participants Who Achieved a Durable Hematocrit Control at Week 48
Durable Hematocrit Control was defined as any participant who achieved phlebotomy eligibility independence from Week 8 to Week 32 and maintained hematocrit control up to 48 weeks after randomization.
Time frame: 48 Weeks
The Percentage of Participants Who Achieved Durable Spleen Volume Reduction at Week 48
Durable Spleen Volume Reduction was defined as a participant who achieved at least 35% reduction from baseline in spleen volume at Week 32 and maintained that response 48 weeks after randomization.
Time frame: 48 Weeks
Estimated Duration of the Primary Response
Duration of the primary response is defined as the time from the first occurrence when both components of the primary endpoint are met until the date of the first documented disease progression (end of response). Kaplan-Meier estimates are provided for duration of primary response.
Time frame: Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study
The Percentage of Participants Who Achieved Overall Clinicohematologic Response at Week 32
Overall Clinicohematologic Response is defined as any participant who achieved a complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera (PV). A Complete Response (CR) is defined as: hematocrit control, spleen volume reduction at least 35% from baseline, platelet count less than or equal to 400 x 10(9)/L, and white blood cell count less than or equal to 10 x 10(9)/L. A Partial Response (PR) is defined as hematocrit control or response in all 3 of the other criteria.
Time frame: 32 Weeks
The Percentage of Participants Achieving a Durable Complete or Partial Clinicohematologic Response at Week 48
Durable Complete or Partial Clinicohematologic Response was defined as any participant who achieved complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera at Week 32 and maintained that response 48 weeks after randomization.
Time frame: 48 Weeks
Estimated Duration of the Complete Hematological Remission
Duration of the complete hematological remission is defined as the time from the first occurrence of complete hematological remission until the date of the first documented progression (end of response). Kaplan-Meier estimates are provided for duration of complete hematological remission.
Time frame: Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study
Duration of the Absence of Phlebotomy Eligibility
Duration of the absence of phlebotomy eligibility is defined as the time from the first occurrence of absence of phlebotomy eligibility until the date of the first documented progression.
Time frame: 256 Weeks
Duration of Reduction in Spleen Volume
Duration of spleen volume reduction is defined as the time from the first occurrence of a \>=35% reduction from baseline in spleen volume until the date of the first documented progression.
Time frame: 256 Weeks
Duration of The Overall Clinicohematologic Response
Duration of the overall clinicohematologic response was defined as the time from the first occurrence of complete response (CR) or partial response (PR) until the date of the first documented disease progression.
Time frame: 256 Weeks
Participants may be treated beyond 256 weeks due to the 14 day visit window.
| Milestone | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Started | 110 | 112 |
| Treated | 110 | 111 |
| Followed for survival | 22 | 21 |
| Completed | 65 | 61 |
| Not completed | 45 | 51 |
| Withdrew: Adverse event | 15 | 13 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Physician decision | 2 | 7 |
| Withdrew: Disease progression | 12 | 11 |
| Withdrew: Protocol deviation | 1 | 1 |
| Withdrew: Participant decision | 10 | 15 |
| Withdrew: Death | 2 | 3 |
| Withdrew: Non-compliance with study treatment | 1 | 0 |
Primary response was defined as having achieved hematocrit control (the absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32) and Spleen Volume Reduction (a greater than or equal to 35% reduction from baseline in spleen volume at Week 32).
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| The Percentage of Participants Achieving a Primary Response at Week 32 | 22.7 (15.3 to 31.7) | 0.9 (0.0 to 4.9) |
Durable Primary Response was defined as any participant who achieved the primary outcome measure and who maintained their response up to 48 weeks after randomization.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| The Percentage of Participants Achieving a Durable Primary Response at Week 48 | 20.0 (13.0 to 28.7) | 0.9 (0.0 to 4.9) |
Complete Hematological Remission at Week 32 was defined as any participant who achieved hematocrit control with a platelet count less than or equal to 400 X 10\^9/L and a white blood cell count less than or equal to 10 X 10\^9/L.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| The Percentage of Participants Achieving Complete Hematological Remission at Week 32 | 23.6 (16.1 to 32.7) | 8.0 (3.7 to 14.7) |
Durable Complete Hematological Remission was defined as any participant who achieved Complete Hematological Remission at Week 32 and maintained their response up to 48 weeks after randomization.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| The Percentage of Participants Who Achieved a Durable Complete Hematological Remission at Week 48 | 20.9 (13.7 to 29.7) | 0.9 (0.0 to 4.9) |
Durable Hematocrit Control was defined as any participant who achieved phlebotomy eligibility independence from Week 8 to Week 32 and maintained hematocrit control up to 48 weeks after randomization.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| The Percentage of Participants Who Achieved a Durable Hematocrit Control at Week 48 | 54.5 (44.8 to 64.1) | 1.8 (0.2 to 6.3) |
Durable Spleen Volume Reduction was defined as a participant who achieved at least 35% reduction from baseline in spleen volume at Week 32 and maintained that response 48 weeks after randomization.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| The Percentage of Participants Who Achieved Durable Spleen Volume Reduction at Week 48 | 37.3 (28.2 to 47.0) | 0.9 (0.0 to 4.9) |
Duration of the primary response is defined as the time from the first occurrence when both components of the primary endpoint are met until the date of the first documented disease progression (end of response). Kaplan-Meier estimates are provided for duration of primary response.
| probability | Ruxolitinib |
|---|---|
| 16 weeks | 1.00 (NA to NA) |
| 32 weeks | 1.00 (NA to NA) |
| 48 weeks | 0.92 (0.72 to 0.98) |
| 64 weeks | 0.92 (0.72 to 0.98) |
| 80 weeks | 0.92 (0.72 to 0.98) |
| 96 weeks | 0.88 (0.67 to 0.96) |
| 112 weeks | 0.84 (0.62 to 0.94) |
| 128 weeks | 0.84 (0.62 to 0.94) |
| 144 weeks | 0.84 (0.62 to 0.94) |
| 160 weeks | 0.79 (0.57 to 0.91) |
| 176 weeks | 0.79 (0.57 to 0.91) |
| 192 weeks | 0.74 (0.51 to 0.88) |
| 208 weeks | 0.74 (0.51 to 0.88) |
| 224 weeks | 0.74 (0.51 to 0.88) |
| 240 weeks | NA (NA to NA) |
| 256 weeks | NA (NA to NA) |
Overall Clinicohematologic Response is defined as any participant who achieved a complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera (PV). A Complete Response (CR) is defined as: hematocrit control, spleen volume reduction at least 35% from baseline, platelet count less than or equal to 400 x 10(9)/L, and white blood cell count less than or equal to 10 x 10(9)/L. A Partial Response (PR) is defined as hematocrit control or response in all 3 of the other criteria.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Complete response rate | 8.2 | 0.9 |
| Partial response rate | 54.5 | 18.8 |
Durable Complete or Partial Clinicohematologic Response was defined as any participant who achieved complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera at Week 32 and maintained that response 48 weeks after randomization.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Complete response rate | 7.3 | 0.9 |
| Partial response rate | 50.9 | 0.9 |
Duration of the complete hematological remission is defined as the time from the first occurrence of complete hematological remission until the date of the first documented progression (end of response). Kaplan-Meier estimates are provided for duration of complete hematological remission.
| probability | Ruxolitinib |
|---|---|
| 16 weeks | 1.00 (NA to NA) |
| 32 weeks | 1.00 (NA to NA) |
| 48 weeks | 0.88 (0.66 to 0.96) |
| 64 weeks | 0.83 (0.61 to 0.93) |
| 80 weeks | 0.74 (0.51 to 0.87) |
| 96 weeks | 0.74 (0.51 to 0.87) |
| 112 weeks | 0.69 (0.46 to 0.84) |
| 128 weeks | 0.69 (0.46 to 0.84) |
| 144 weeks | 0.65 (0.41 to 0.81) |
| 160 weeks | 0.65 (0.41 to 0.81) |
| 176 weeks | 0.55 (0.32 to 0.73) |
| 192 weeks | 0.55 (0.32 to 0.73) |
| 208 weeks | 0.55 (0.32 to 0.73) |
| 224 weeks | 0.55 (0.32 to 0.73) |
| 240 weeks | NA (NA to NA) |
| 256 weeks | NA (NA to NA) |
Duration of the absence of phlebotomy eligibility is defined as the time from the first occurrence of absence of phlebotomy eligibility until the date of the first documented progression.
| probability | Ruxolitinib |
|---|---|
| 16 weeks | 1.00 (NA to NA) |
| 32 weeks | 1.00 (NA to NA) |
| 48 weeks | 0.97 (0.88 to 0.99) |
| 64 weeks | 0.92 (0.82 to 0.97) |
| 80 weeks | 0.91 (0.80 to 0.96) |
| 96 weeks | 0.91 (0.80 to 0.96) |
| 112 weeks | 0.87 (0.76 to 0.93) |
| 128 weeks | 0.84 (0.72 to 0.91) |
| 144 weeks | 0.84 (0.72 to 0.91) |
| 160 weeks | 0.82 (0.70 to 0.90) |
| 176 weeks | 0.79 (0.66 to 0.87) |
| 192 weeks | 0.77 (0.64 to 0.86) |
| 208 weeks | 0.73 (0.60 to 0.83) |
| 224 weeks | 0.73 (0.60 to 0.83) |
| 240 weeks | 0.73 (0.60 to 0.83) |
| 256 weeks | 0.73 (0.60 to 0.83) |
Duration of spleen volume reduction is defined as the time from the first occurrence of a \>=35% reduction from baseline in spleen volume until the date of the first documented progression.
| probability | Ruxolitinib |
|---|---|
| 16 weeks | 1.00 (NA to NA) |
| 32 weeks | 1.00 (NA to NA) |
| 48 weeks | 1.00 (NA to NA) |
| 64 weeks | 1.00 (NA to NA) |
| 80 weeks | 1.00 (NA to NA) |
| 96 weeks | 0.98 (0.84 to 1.00) |
| 112 weeks | 0.95 (0.82 to 0.99) |
| 128 weeks | 0.95 (0.82 to 0.99) |
| 144 weeks | 0.95 (0.82 to 0.99) |
| 160 weeks | 0.93 (0.79 to 0.98) |
| 176 weeks | 0.93 (0.79 to 0.98) |
| 192 weeks | 0.93 (0.79 to 0.98) |
| 208 weeks | 0.87 (0.66 to 0.95) |
| 224 weeks | 0.72 (0.34 to 0.91) |
| 240 weeks | NA (NA to NA) |
| 256 weeks | NA (NA to NA) |
Duration of the overall clinicohematologic response was defined as the time from the first occurrence of complete response (CR) or partial response (PR) until the date of the first documented disease progression.
| probability | Ruxolitinib |
|---|---|
| 16 weeks | 1.00 (NA to NA) |
| 32 weeks | 0.99 (0.90 to 1.00) |
| 48 weeks | 0.96 (0.87 to 0.99) |
| 64 weeks | 0.91 (0.81 to 0.96) |
| 80 weeks | 0.88 (0.78 to 0.94) |
| 96 weeks | 0.88 (0.78 to 0.94) |
| 112 weeks | 0.85 (0.74 to 0.92) |
| 128 weeks | 0.82 (0.71 to 0.89) |
| 144 weeks | 0.82 (0.71 to 0.89) |
| 160 weeks | 0.80 (0.69 to 0.88) |
| 176 weeks | 0.75 (0.63 to 0.84) |
| 192 weeks | 0.70 (0.57 to 0.80) |
| 208 weeks | 0.67 (0.54 to 0.77) |
| 224 weeks | 0.67 (0.54 to 0.77) |
| 240 weeks | 0.67 (0.54 to 0.77) |
| 256 weeks | 0.67 (0.54 to 0.77) |
Collected over The initial data reported was for the study up to Week 32. This time frame defines the comparative phase of the study where the majority of participants remained on their original randomized assignment and exposure between ruxolitinib and best available therapy was similar. Data inclusive of end of study was reported up to week 256 for Ruxolitinib group. Long term Follow Up for BAT was not reported as all patients have completed the study or crossed over to Ruxolitinib group by week 80.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib - Through Week 32 | — | 15/110 (13.6%) | 105/110 (95.5%) |
| Best Available Therapy - Through Week 32 | — | 10/111 (9%) | 104/111 (93.7%) |
| Ruxolitinib - Week 256 Close Out | — | 44/110 (40%) | 107/110 (97.3%) |
| Event | Ruxolitinib - Through Week 32 | Best Available Therapy - Through Week 32 | Ruxolitinib - Week 256 Close Out |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/110 | 1/111 | 5/110 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/110 | 0/111 | 4/110 |
| Atrial fibrillationCardiac disorders | 0/110 | 1/111 | 3/110 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/110 | 0/111 | 3/110 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/110 | 0/111 | 3/110 |
| Chest painGeneral disorders | 1/110 | 0/111 | 2/110 |
| DehydrationMetabolism and nutrition disorders | 0/110 | 0/111 | 2/110 |
| Metastatic squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/110 | 0/111 | 2/110 |
| Rectal haemorrhageGastrointestinal disorders | 0/110 | 0/111 | 2/110 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/110 | 0/111 | 2/110 |
| Event | Ruxolitinib - Through Week 32 | Best Available Therapy - Through Week 32 | Ruxolitinib - Week 256 Close Out |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 20/110 | 3/111 | 38/110 |
| DiarrhoeaGastrointestinal disorders | 16/110 | 8/111 | 30/110 |
| PruritusSkin and subcutaneous tissue disorders | 15/110 | 25/111 | 30/110 |
| Weight increasedInvestigations | 6/110 | 1/111 | 26/110 |
| HeadacheNervous system disorders | 18/110 | 21/111 | 25/110 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/110 | 7/111 | 24/110 |
| FatigueGeneral disorders | 16/110 | 17/111 | 22/110 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 13/110 | 5/111 | 22/110 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/110 | 6/111 | 20/110 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 11/110 | 2/111 | 19/110 |
All enrolled participants, regardless treated or not.
| Age, Continuous(years) | Ruxolitinib | Best Available Therapy | Total |
|---|---|---|---|
| Mean | 61.1 ± 10.48 | 59.1 ± 10.25 | 60.1 ± 10.39 |
| Age, Customized(participants) | Ruxolitinib | Best Available Therapy | Total |
|---|---|---|---|
| < 60 years | 49 | 54 | 103 |
| ≥ 60 years | 61 | 58 | 119 |
| Sex: Female, Male(Participants) | Ruxolitinib | Best Available Therapy | Total |
|---|---|---|---|
| Female | 44 | 32 | 76 |
| Male | 66 | 80 | 146 |
| Race/Ethnicity, Customized(participants) | Ruxolitinib | Best Available Therapy | Total |
|---|---|---|---|
| White/Caucasian | 98 | 96 | 194 |
| Black/African American | 1 | 0 | 1 |
| Asian | 11 | 16 | 27 |
| Weight(kg) | Ruxolitinib | Best Available Therapy | Total |
|---|---|---|---|
| Mean | 76.6 ± 14.09 | 79.0 ± 17.34 | 77.8 ± 15.83 |
| Height(cm) | Ruxolitinib | Best Available Therapy | Total |
|---|---|---|---|
| Mean | 172.2 ± 8.44 | 173.3 ± 9.79 | 172.8 ± 9.14 |
| Body Mass Index (BMI)(kg/m^2) | Ruxolitinib | Best Available Therapy | Total |
|---|---|---|---|
| Mean | 25.8 ± 3.82 | 26.1 ± 4.24 | 25.9 ± 4.03 |
| ECOG performance status(participants) | Ruxolitinib | Best Available Therapy | Total |
|---|---|---|---|
| 0 | 76 | 77 | 153 |
| 1 | 31 | 34 | 65 |
| 2 | 3 | 1 | 4 |
Showing the first 100 of 102 sites across 18 countries. Choose a country and city above to see the rest.
Ran from Oct 2010 to primary completion in Jan 2014, 38 months.
Results were first posted in Mar 2015, 1 year 1 month after primary completion. A results delay was requested in Dec 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib